{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T23:00:09Z","timestamp":1762642809320,"version":"build-2065373602"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,26]],"date-time":"2022-12-26T00:00:00Z","timestamp":1672012800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ijidonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Infectious Diseases"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.ijid.2022.12.034","type":"journal-article","created":{"date-parts":[[2022,12,29]],"date-time":"2022-12-29T20:10:13Z","timestamp":1672344613000},"page":"166-175","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Heterologous prime-boost immunization with ChAdOx1-S and BNT162b2: reactogenicity and immunogenicity in a prospective cohort study"],"prefix":"10.1016","volume":"128","author":[{"given":"Niko","family":"Kohmer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shivana","family":"Stein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Schenk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1102-078X","authenticated-orcid":false,"given":"Katharina","family":"Grikscheit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melinda","family":"Metzler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Holger F.","family":"Rabenau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5417-9307","authenticated-orcid":false,"given":"Marek","family":"Widera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0662-6675","authenticated-orcid":false,"given":"Eva","family":"Herrmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6726-1614","authenticated-orcid":false,"given":"Sabine","family":"Wicker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Ciesek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijid.2022.12.034_bib0001","unstructured":"European Medicines Agency. Signal assessment report on embolic and thrombotic events (SMQ) with COVID-19 Vaccine (ChAdOx1-S [recombinant]) \u2013 Vaxzevria (previously COVID-19 Vaccine AstraZeneca) (Other viral vaccines), https:\/\/www.ema.europa.eu\/en\/documents\/prac-recommendation\/signal-assessment-report-embolic-thrombotic-events-smq-covid-19-vaccine-chadox1-s-recombinant_en.pdf; 2021 [accessed 19 August 2022]."},{"key":"10.1016\/j.ijid.2022.12.034_bib0002","unstructured":"Robert Koch Institut. Beschluss der STIKO zur 4. Aktualisierung der COVID-19 Impfempfehlung, https:\/\/www.rki.de\/DE\/Content\/Infekt\/EpidBull\/Archiv\/2021\/Ausgaben\/16_21.pdf?__blob=publicationFile; 2021 [accessed 19 August 2022]."},{"key":"10.1016\/j.ijid.2022.12.034_bib0003","unstructured":"Robert Koch Institut. COVID-19-Zielimpfquote: STIKO: 8. Aktualisierung der COVID-19-Impfempfehlung VRE-Jahresbericht, https:\/\/www.rki.de\/DE\/Content\/Infekt\/EpidBull\/Archiv\/2021\/Ausgaben\/27_21.pdf?__blob=publicationFile; 2021 [accessed 19 August 2022]."},{"key":"10.1016\/j.ijid.2022.12.034_bib0004","doi-asserted-by":"crossref","first-page":"798","DOI":"10.3390\/vaccines10050798","article-title":"Immunogenicity and safety of homologous and heterologous prime-boost immunization with COVID-19 vaccine: systematic review and meta-analysis","volume":"10","author":"Cheng","year":"2022","journal-title":"Vaccines"},{"key":"10.1016\/j.ijid.2022.12.034_bib0005","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1080\/14760584.2021.1971522","article-title":"To mix or not to mix? A rapid systematic review of heterologous prime-boost Covid-19 vaccination","volume":"20","author":"Chiu","year":"2021","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.ijid.2022.12.034_bib0006","doi-asserted-by":"crossref","first-page":"857","DOI":"10.3390\/vaccines9080857","article-title":"Heterologous ChAdOx1 nCoV-19\/BNT162b2 prime-boost vaccination induces strong humoral responses among health care workers","volume":"9","author":"Benning","year":"2021","journal-title":"Vaccines"},{"key":"10.1016\/j.ijid.2022.12.034_bib0007","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S2213-2600(21)00357-X","article-title":"Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study","volume":"9","author":"Hillus","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.ijid.2022.12.034_bib0008","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/S0140-6736(21)01694-9","article-title":"Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial","volume":"398","author":"Liu","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ijid.2022.12.034_bib0009","unstructured":"Robert Koch Institut. STIKO: 14. Aktualisierung der COVID-19 Impfempfehlung. Reiseassoziierte Infektionskrankheiten 2020, https:\/\/www.rki.de\/DE\/Content\/Infekt\/EpidBull\/Archiv\/2021\/Ausgaben\/48_21.pdf?__blob=publicationFile; 2021 [accessed 19 August 2022]."},{"key":"10.1016\/j.ijid.2022.12.034_bib0010","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1016\/j.jinf.2022.03.006","article-title":"Comparative T and B immune responses of four different anti-COVID-19 vaccine strategies 6 months after vaccination","volume":"84","author":"Bonnet","year":"2022","journal-title":"J Infect"},{"key":"10.1016\/j.ijid.2022.12.034_bib0011","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(21)01420-3","article-title":"Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial","volume":"398","author":"Borobia","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ijid.2022.12.034_bib0012","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2021.26.28.2100634","article-title":"Real-world data shows increased reactogenicity in adults after heterologous compared to homologous prime-boost COVID-19 vaccination, March\u2013June 2021, England","volume":"26","author":"Powell","year":"2021","journal-title":"Euro Surveill"},{"key":"10.1016\/j.ijid.2022.12.034_bib0013","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1016\/S0140-6736(21)01115-6","article-title":"Com-COV study group. heterologous prime-boost COVID-19 vaccination: initial reactogenicity data","volume":"397","author":"Shaw","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ijid.2022.12.034_bib0014","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1186\/s12879-022-07443-x","article-title":"Reactogenicity after heterologous and homologous COVID-19 prime-boost vaccination regimens: descriptive interim results of a comparative observational cohort study","volume":"22","author":"Warkentin","year":"2022","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.ijid.2022.12.034_bib0015","first-page":"150","article-title":"Immunogenicity and safety of homologous and heterologous ChAdOx1-S and mRNA-1273 vaccinations in healthy adults in Taiwan","author":"Kang","year":"2022","journal-title":"J Clin Virol"},{"key":"10.1016\/j.ijid.2022.12.034_bib0016","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1038\/s41591-021-01464-w","article-title":"Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19\/mRNA vaccination","volume":"27","author":"Schmidt","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.ijid.2022.12.034_bib0017","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1056\/NEJMoa2116414","article-title":"Homologous and heterologous Covid-19 booster vaccinations","volume":"386","author":"Atmar","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijid.2022.12.034_bib0018","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1056\/NEJMc2103916","article-title":"Antibody persistence through 6 months after the second dose of mRNA-1273 vaccine for Covid-19","volume":"384","author":"Doria-Rose","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijid.2022.12.034_bib0019","doi-asserted-by":"crossref","first-page":"4710","DOI":"10.1038\/s41467-022-32321-0","article-title":"Comparative immunogenicity and reactogenicity of heterologous ChAdOx1-nCoV-19-priming and BNT162b2 or mRNA-1273-boosting with homologous COVID-19 vaccine regimens","volume":"13","author":"Klemis","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.ijid.2022.12.034_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.112650","article-title":"Reactogenicity and immunogenicity of heterologous prime-boost immunization with COVID-19 vaccine","volume":"147","author":"Nguyen","year":"2022","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.ijid.2022.12.034_bib0021","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.jinf.2022.01.038","article-title":"Real-world data on immune responses following heterologous prime-boost COVID-19 vaccination schedule with Pfizer and AstraZeneca vaccines in England","volume":"84","author":"Westrop","year":"2022","journal-title":"J Infect"},{"key":"10.1016\/j.ijid.2022.12.034_bib0022","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.896151","article-title":"Cellular and humoral immune response to a third dose of BNT162b2 COVID-19 vaccine \u2013 a prospective observational study","volume":"13","author":"Herzberg","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.ijid.2022.12.034_bib0023","doi-asserted-by":"crossref","first-page":"4872","DOI":"10.1038\/s41467-022-32527-2","article-title":"BNT162b2-boosted immune responses six months after heterologous or homologous ChAdOx1nCoV-19\/BNT162b2 vaccination against COVID-19","volume":"13","author":"Behrens","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.ijid.2022.12.034_bib0024","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.3390\/jcm10102128","article-title":"Utility of different surrogate enzyme-linked immunosorbent assays (sELISAs) for detection of SARS-CoV-2 neutralizing antibodies","volume":"10","author":"Kohmer","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.ijid.2022.12.034_bib0025","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s12916-021-02231-x","article-title":"Humoral immune response after different SARS-CoV-2 vaccination regimens","volume":"20","author":"Rose","year":"2022","journal-title":"BMC Med"},{"key":"10.1016\/j.ijid.2022.12.034_bib0026","article-title":"Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory B and T cells","volume":"2","author":"Cohen","year":"2021","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.ijid.2022.12.034_bib0027","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/s41586-021-03696-9","article-title":"Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection","volume":"595","author":"Wang","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.ijid.2022.12.034_bib0028","unstructured":"UK Health Security Agency. SARS-CoV-2 variants of concern and variants under investigation in England: technical Briefing 34, https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/1050236\/technical-briefing-34-14-january-2022.pdf; 2022 (accessed 19 August 2022)."},{"key":"10.1016\/j.ijid.2022.12.034_bib0029","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1056\/NEJMc2119912","article-title":"SARS-CoV-2 omicron variant neutralization after mRNA-1273 booster vaccination","volume":"386","author":"Pajon","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijid.2022.12.034_bib0030","doi-asserted-by":"crossref","first-page":"104158","DOI":"10.1016\/j.ebiom.2022.104158","article-title":"Limited neutralisation of the SARS-CoV-2 Omicron subvariants BA.1 and BA.2 by convalescent and vaccine serum and monoclonal antibodies","volume":"82","author":"Wilhelm","year":"2022","journal-title":"eBioMedicine"},{"key":"10.1016\/j.ijid.2022.12.034_bib0031","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41423-021-00836-z","article-title":"Increased immune escape of the new SARS-CoV-2 variant of concern Omicron","volume":"19","author":"Hu","year":"2022","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.ijid.2022.12.034_bib0032","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/s41586-021-04388-0","article-title":"Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2","volume":"602","author":"Liu","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.ijid.2022.12.034_bib0033","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/s41586-021-04389-z","article-title":"Considerable escape of SARS-CoV-2 Omicron to antibody neutralization","volume":"602","author":"Planas","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.ijid.2022.12.034_bib0034","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","article-title":"Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection","volume":"27","author":"Khoury","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.ijid.2022.12.034_bib0035","doi-asserted-by":"crossref","first-page":"e52","DOI":"10.1016\/S2666-5247(21)00267-6","article-title":"Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis","volume":"3","author":"Cromer","year":"2022","journal-title":"Lancet Microbe"},{"key":"10.1016\/j.ijid.2022.12.034_bib0036","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1056\/NEJMoa2035002","article-title":"REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19","volume":"384","author":"Weinreich","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijid.2022.12.034_bib0037","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1093\/infdis\/jiab355","article-title":"Limited neutralization of authentic severe acute respiratory syndrome coronavirus 2 variants carrying E484K in vitro","volume":"224","author":"Widera","year":"2021","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijid.2022.12.034_bib0038","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1186\/s12879-022-07814-4","article-title":"High vaccine effectiveness against severe COVID-19 in the elderly in Finland before and after the emergence of Omicron","volume":"22","author":"Baum","year":"2022","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.ijid.2022.12.034_bib0039","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.32760","article-title":"Effectiveness of COVID-19 vaccines against Omicron or Delta symptomatic infection and severe outcomes","volume":"5","author":"Buchan","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.ijid.2022.12.034_bib0040","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1038\/s41467-022-30895-3","article-title":"Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar","volume":"13","author":"Chemaitelly","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.ijid.2022.12.034_bib0041","doi-asserted-by":"crossref","first-page":"139","DOI":"10.15585\/mmwr.mm7104e3","volume":"71","author":"Thompson","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.ijid.2022.12.034_bib0042","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/j.cell.2020.09.038","article-title":"Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity","volume":"183","author":"Rydyznski Moderbacher","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.ijid.2022.12.034_bib0043","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.108728","article-title":"Early induction of functional SARS-CoV-2-specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients","volume":"34","author":"Tan","year":"2021","journal-title":"Cell Rep"},{"key":"10.1016\/j.ijid.2022.12.034_bib0044","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1038\/s41591-022-01700-x","article-title":"Ancestral SARS-CoV-2-specific T cells cross-recognize the Omicron variant","volume":"28","author":"Gao","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.ijid.2022.12.034_bib0045","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abo2202","article-title":"Divergent SARS-CoV-2 Omicron-reactive T and B cell responses in COVID-19 vaccine recipients","volume":"7","author":"GeurtsvanKessel","year":"2022","journal-title":"Sci Immunol"},{"key":"10.1016\/j.ijid.2022.12.034_bib0046","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/s41586-022-04460-3","article-title":"T cell responses to SARS-CoV-2 spike cross-recognize Omicron","volume":"603","author":"Keeton","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.ijid.2022.12.034_bib0047","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.104073","article-title":"Heterologous ChAdOx1\/BNT162b2 vaccination induces stronger immune response than homologous ChAdOx1 vaccination: the pragmatic, multi-center, three-arm, partially randomized HEVACC trial","volume":"80","author":"B\u00e1nki","year":"2022","journal-title":"EBiomedicine"}],"container-title":["International Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971222006725?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971222006725?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T08:11:43Z","timestamp":1761120703000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1201971222006725"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":47,"alternative-id":["S1201971222006725"],"URL":"https:\/\/doi.org\/10.1016\/j.ijid.2022.12.034","relation":{},"ISSN":["1201-9712"],"issn-type":[{"type":"print","value":"1201-9712"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Heterologous prime-boost immunization with ChAdOx1-S and BNT162b2: reactogenicity and immunogenicity in a prospective cohort study","name":"articletitle","label":"Article Title"},{"value":"International Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijid.2022.12.034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.","name":"copyright","label":"Copyright"}]}}